Related Experiment Video
Updated: Jul 4, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Moxifloxacin: a respiratory fluoroquinolone
Marc Miravitlles1, Antonio Anzueto
1Servei de Pneumologia, Institut Clínic del Tòrax (IDIBAPS), Ciber de Enfermedades Respiratorias (CIBERES), Hospital Clínic, Barcelona, Spain. marcm@clinic.ub.es
Moxifloxacin effectively treats common respiratory infections like pneumonia and bronchitis, offering faster symptom relief and high eradication rates. It is recognized in guidelines for moderate to severe community and hospital-acquired infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Respiratory Medicine
Background:
- Respiratory quinolones are potent antimicrobials targeting common respiratory pathogens.
- Moxifloxacin, a fourth-generation fluoroquinolone, exhibits broad-spectrum activity against Gram-positive, Gram-negative, and atypical strains, including multi-drug resistant Streptococcus pneumoniae.
Purpose of the Study:
- To systematically review and update the clinical efficacy of moxifloxacin.
- Focus on its role in treating various respiratory tract infections.
Main Methods:
- Systematic review of published literature.
- Analysis of clinical studies evaluating moxifloxacin's efficacy in respiratory infections.
Main Results:
- Moxifloxacin demonstrated clinical efficacy in community-acquired pneumonia, chronic bronchitis exacerbations, and acute bacterial rhinosinusitis.
- Faster symptom resolution observed in community-acquired pneumonia and chronic bronchitis patients compared to first-line treatments.
- Achieved excellent bacterial eradication rates in treated patients.
Conclusions:
- Moxifloxacin is recognized in international guidelines for treating moderate to severe respiratory infections.
- Recommended as a first-line therapy option in both community and hospital settings.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Upper Respiratory Drugs: Decongestants
Most decongestants are readily available over-the-counter in various...

